Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge
Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved..
With the advent of new cellular and targeted therapies, treatment options for relapsed and refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best outcomes remains a matter of passionate debate. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is still considered a treatment option for patients with chemosensitive lymphoma when cure is the expected goal. The myeloablative conditioning regimen preceding the stem cell infusion is considered the effective component of this approach. Carmustine (BCNU)-based preparative regimens, such as BEAM and BEAC, are considered the standard of care and have shown efficacy and low nonrelapse mortality (NRM). Comparative studies between conditioning regimens have failed to identify a better option. After a BCNU drug shortage in Canada followed by a steep increase in price, we elected to substitute BCNU for bendamustine (benda) in the preparative regimen. The purpose of this substitution was to improve response while preserving safety and controlling costs. From May 2015 to May 2018, a total of 131 consecutive lymphoma patients received benda-EAM conditioning. These patients were compared with 96 consecutive patients who received BCNU-based conditioning from January 2012 to May 2015. Apart from conditioning, supportive care measures were the same in the 2 groups. Patients receiving benda were older (55.7 years versus 51.1 years; P = .002). The development of grade ≥3 mucositis was more frequent with benda conditioning (39.5% versus 7.8%; P < .001) leading to a greater requirement for parenteral nutrition (48.9% versus 21.9%; P < .001). A transient creatinine increase >1.5 times the upper limit of normal (15.3% versus 4.2%; P < .008) and intensive care unit admission (6.9% versus 1.1%; P < .029) were more frequent with benda; however, there were no between-group differences in cardiac, pulmonary, or liver toxicity and NRM. With a median follow-up of 48 months for the benda group and 60 months for the BCNU group, benda was associated with significantly better progression-free survival (71% versus 61%; P = .040; hazard ratio [HR], 1.6; 95% confidence interval [CI], 1.0 to 2.7) and overall survival (86% vs 71%; P = .0066; HR, 2.6; 95% CI, 1.3 to 5.4) compared with BCNU-based conditioning regimens. While novel therapies emerge, our study demonstrates that benda-EAM is safe and effective and should be considered a valid alternative to BCNU conditioning to improve outcomes of patients with chemosensitive r/R lymphomas undergoing ASCT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Transplantation and cellular therapy - 29(2023), 1 vom: 16. Jan., Seite 34.e1-34.e7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lachance, Sylvie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04079A1RDZ |
|---|
| Anmerkungen: |
Date Completed 10.01.2023 Date Revised 07.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jtct.2022.10.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347583083 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347583083 | ||
| 003 | DE-627 | ||
| 005 | 20231226034153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtct.2022.10.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347583083 | ||
| 035 | |a (NLM)36243319 | ||
| 035 | |a (PII)S2666-6367(22)01698-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lachance, Sylvie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2023 | ||
| 500 | |a Date Revised 07.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a With the advent of new cellular and targeted therapies, treatment options for relapsed and refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best outcomes remains a matter of passionate debate. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is still considered a treatment option for patients with chemosensitive lymphoma when cure is the expected goal. The myeloablative conditioning regimen preceding the stem cell infusion is considered the effective component of this approach. Carmustine (BCNU)-based preparative regimens, such as BEAM and BEAC, are considered the standard of care and have shown efficacy and low nonrelapse mortality (NRM). Comparative studies between conditioning regimens have failed to identify a better option. After a BCNU drug shortage in Canada followed by a steep increase in price, we elected to substitute BCNU for bendamustine (benda) in the preparative regimen. The purpose of this substitution was to improve response while preserving safety and controlling costs. From May 2015 to May 2018, a total of 131 consecutive lymphoma patients received benda-EAM conditioning. These patients were compared with 96 consecutive patients who received BCNU-based conditioning from January 2012 to May 2015. Apart from conditioning, supportive care measures were the same in the 2 groups. Patients receiving benda were older (55.7 years versus 51.1 years; P = .002). The development of grade ≥3 mucositis was more frequent with benda conditioning (39.5% versus 7.8%; P < .001) leading to a greater requirement for parenteral nutrition (48.9% versus 21.9%; P < .001). A transient creatinine increase >1.5 times the upper limit of normal (15.3% versus 4.2%; P < .008) and intensive care unit admission (6.9% versus 1.1%; P < .029) were more frequent with benda; however, there were no between-group differences in cardiac, pulmonary, or liver toxicity and NRM. With a median follow-up of 48 months for the benda group and 60 months for the BCNU group, benda was associated with significantly better progression-free survival (71% versus 61%; P = .040; hazard ratio [HR], 1.6; 95% confidence interval [CI], 1.0 to 2.7) and overall survival (86% vs 71%; P = .0066; HR, 2.6; 95% CI, 1.3 to 5.4) compared with BCNU-based conditioning regimens. While novel therapies emerge, our study demonstrates that benda-EAM is safe and effective and should be considered a valid alternative to BCNU conditioning to improve outcomes of patients with chemosensitive r/R lymphomas undergoing ASCT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autologous stem cell transplant | |
| 650 | 4 | |a Chemosensitive | |
| 650 | 4 | |a Conditioning optimization | |
| 650 | 4 | |a Lymphoma | |
| 650 | 7 | |a Bendamustine Hydrochloride |2 NLM | |
| 650 | 7 | |a 981Y8SX18M |2 NLM | |
| 650 | 7 | |a Carmustine |2 NLM | |
| 650 | 7 | |a U68WG3173Y |2 NLM | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a Melphalan |2 NLM | |
| 650 | 7 | |a Q41OR9510P |2 NLM | |
| 700 | 1 | |a Bourguignon, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Boisjoly, Josie-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Bouchard, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Imran |e verfasserin |4 aut | |
| 700 | 1 | |a Bambace, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Bernard, Léa |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Delisle, Jean-Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Fleury, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Kiss, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mollica, Luigina |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Denis-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Sauvageau, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Veilleux, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Zehr, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Chagnon, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Jean |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation and cellular therapy |d 2021 |g 29(2023), 1 vom: 16. Jan., Seite 34.e1-34.e7 |w (DE-627)NLM307596486 |x 2666-6367 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:1 |g day:16 |g month:01 |g pages:34.e1-34.e7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtct.2022.10.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 1 |b 16 |c 01 |h 34.e1-34.e7 | ||